[{"id":"72b6e296-999e-4af6-965d-02f44a6823a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039892","created_at":"2021-09-10T16:57:16.515Z","updated_at":"2024-07-02T16:35:21.555Z","phase":"Phase 2","brief_title":"Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05039892","lead_sponsor":"3D Medicines (Beijing) Co., Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e segigratinib (3D185)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-01-31"}]